CRP and arthropathy: Additionally, another meta-analysis by Wu et al. revealed that the combination of IGU and MTX in the treatment of RA leads to superior efficacy in increasing ACR20/50/70 response rates, reducing ESR, CRP, assessing the activity of 28 joint diseases, and VAS scores compared to individual use, without a significant increase in adverse reactions (Wu et al., 2018).